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Abstract
Introduction: Plasmablastic lymphoma is an aggressive non-Hodgkin lymphoma classically occurring in individuals
infected with HIV. Plasmablastic lymphoma has a predilection for the oral cavity and jaw. However, recent case
reports have shown lymphoma in the stomach, lung, nasal cavity, cervical lymph nodes and jejunum in HIV-
negative individuals. We report what is, to the best of our knowledge, the first case of plasmablastic lymphoma
occurring in the ano-rectal junction of an HIV-negative man.
Case Presentation: A previously healthy 59-year-old Caucasian man presented with painless rectal bleeding.
Colonoscopy revealed a lesion in the ano-rectal junction, with pathological examination demonstrating atypical
lymphoid cells consisting primarily of plasmablasts with rounded nuclei, coarse chromatin, small nucleoli and
multiple mitotic figures. Immunohistochemical analysis showed the atypical cells were negative for CD45, CD20,
CD79a and immunoglobulin light chains, but were strongly positive for CD138 and EBV-encoded RNA. The results
were consistent with a diagnosis of plasmablastic lymphoma. Aggressive systemic chemotherapy and involved field
radiation therapy resulted in complete clinical and pathological remission.
Conclusion: Increasing awareness of plasmablastic lymphoma in HIV-negative individuals and in this location is
warranted.
Introduction
Plasmablastic lymphoma (PBL) is most frequently an
AIDS-related non-Hodgkin lymphoma (NHL) and is
usually confined to the oral cavity and jaws, although
involvement of distant sites may occur [1-6]. It is a rapidly
progressive tumor usually seen in human immunodefi-
ciency virus (HIV) infection with advanced immunodefi-
ciency (CD4<200 cells/ml) and, like NHL, is an AIDS
defining illness [7,8]. In recent years, cases of PBL have
been reported involving the lungs [9], stomach [10], cervi-
cal lymph nodes [11], nasal cavity [12] and jejunum [13] in
HIV-negative individuals. We report the first case of PBL
to be found in the ano-rectum of an HIV- negative man.
Case presentation
A 59-year-old heterosexual Caucasian man presented
with recurrent and profuse rectal bleeding. Past medical
history was remarkable for an ischiorectal abscess, with
no apparent predisposing conditions, which was incised
and drained. Eventually our patient had developed an
anal fistula which was managed with Tisseel
® (a surgical
adhesive composed from fibrinogen and thrombin).
Later a seton, a length of suture material looped
through a fistula to keep it open and allow pus to drain,
was inserted. The seton was exchanged and tightened
on three occasions and eventually was extruded. Physical
examination at that time showed no remaining fistula.
Our patient was investigated with a gastrointestinal ser-
ies and colonoscopy which were negative for inflamma-
tory bowel disease and malignancy.
At lymphoma presentation, the history was otherwise
unremarkable; in particular, there was no history of
noticeable lumps, unexplained fevers, drenching sweats,
or weight loss. There were no symptoms related to cyto-
penia. General physical examination was unremarkable,
with no palpable lymphadenopathy or hepatosplenome-
galy. Digital rectal examination showed scarring of his
* Correspondence: mab977@mail.usask.ca
Department of Medicine, Division of Gastroenterology & Hematology, St
Paul’s Hospital, Vancouver, BC, V5Z 1M9, Canada
Brahmania et al. Journal of Medical Case Reports 2011, 5:168
http://www.jmedicalcasereports.com/content/5/1/168 JOURNAL OF MEDICAL
CASE REPORTS
© 2011 Brahmania et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.right peri-anal area and a small, tender, ulcerated mass
was palpable in his anal canal at the nine o’clock lithot-
omy position. There was no blood on the examining
glove. Laboratory investigations showed his complete
blood count (CBC), electrolytes, liver panel, calcium,
and lactate dehydrogenase levels to be within normal
range. A serum protein electrophoresis showed no
monoclonal protein; however there was a slight decrease
in the gamma fraction at 8 g/L (lower limit of normal
10 g/L). A screen for hepatitis B and C was negative, as
was serology for varicella zoster virus, Epstein-Barr virus
(EBV), cytomegalovirus, herpes simplex virus and HIV.
Our patient underwent a colonoscopy which showed a
normal colon apart from a 5 mm polyp at 20 cm which
was hyperplastic by pathologic examination. At the ano-
rectal junction, a hypervascular cauliflower-like mass of
3 mm was seen and biopsied (Figure 1). Histopathologi-
cal examination demonstrated abundant atypical large
lymphoid cells with lesser numbers of plasma cells. The
atypical lymphoid cell population consisted predomi-
nantly of plasmablasts with rounded nuclei, coarse chro-
matin, small nucleoli and multiple mitotic figures.
Immunohistochemical analysis showed the atypical cells
were negative for CD3, CD5, CD10, CD20, CD30,
CD45, CD56, BCL-2, BCL-6, CD45 (Figure 2a), CD20
(Figure 2b), CD79a. Furthermore, we could not detect
any restriction of immunoglobulin light chains (kappa
or lambda), or expression of immunoglobulin heavy
chains IgG, IgM, IgD; however there was cytoplasmic
expression of IgA. In contrast, the neoplastic cells were
strongly positive for MUM1, epithelial membrane anti-
gen, CD38, CD138 (Figure 2c) and EBV-encoded RNA
(EBER) (Figure 2d). There was no expression of LANA-
1. The proliferation index by Ki-67 immunohistochemis-
try was approximately 70%. The results were consistent
with a diagnosis of PBL.
Staging investigations included a computed tomogra-
phy (CT) scan of the chest, abdomen and pelvis, which
showed no evidence of lymphoma in these other sites. A
bone marrow aspirate and biopsy was negative for lym-
phoma. Our patient was staged as Ann Arbor 1A (Addi-
tional file 1: Table S1), and was low risk according to
the International Prognostic Index. Our patient subse-
quently underwent gallium scanning, which showed
increased activity in his right inguinal region (2 cm),
suggestive of gallium avid lymphoma.
Our patient was treated with three cycles of CHOP
chemotherapy (cyclophosphamide, doxorubicin, vincris-
tine and prednisolone), in full doses and on schedule,
followed by involved field radiation therapy to the ano-
rectal region, pelvic nodes, and right inguinal nodes.
The chemotherapeutic regimen and radiation therapy
were well tolerated by our patient and no complications
were reported. A CT scan done following therapy
showed complete resolution of previously detected
abnormalities. CT scanning at six months from lym-
phoma diagnosis showed no evidence of recurrence.
Most recent clinical follow up was done five years from
diagnosis with rectal examination and colonoscopy
showing ongoing remission.
Discussion
PBL is usually diagnosed in the context of HIV infec-
tion, however in recent years it has also been reported
in a number of sites in HIV-negative individuals [9-13].
As seen from our case report, it can also be found in
the hindgut. Derived from B-cells, PBL has distinct mor-
phologic and immunophenotypic features by which it
has been defined [14,15]. PBL has some morphologic
characteristics similar to diffuse large B-cell lymphoma
(DLBCL) and the World Health Organization classifies
PBL as a variant of DLBCL. However, PBL is differen-
tiated from DLBCL by minimal or no expression of
CD20 and leukocyte common antigen. Instead, PBL has
been characterized by the plasmablastic morphology of
the neoplastic cells, with numerous mitotic figures, the
expression of plasma cell markers such as VS38c and
CD138/syndecan-1 [1,3,15] and EBER positivity [16].
PBL has been shown to have an immunophenotype
and tumor suppressor gene expression profile virtually
identical to that of the plasmablastic variant of plasma
cell myeloma. In contrast, this profile is unlike that of
DLBCL, suggesting a cell of origin more in keeping with
myeloma than NHL. However, unlike myeloma, and
unlike the majority of DLBCL in immunocompetent
individuals, it was found that most HIV-positive patients
with PBL were EBER-positive [16].
Evidence supporting a pathogenic role for human
herpes-virus-8/Kaposi’s sarcoma-associated herpes virus





Figure 1 Mass at the ano-rectal junction.
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cases of PBL and/or multicentric Castleman’sd i s e a s e
[17-20]. In these disorders, an interaction between HIV
and HHV-8 has been suggested, whereby viral interleu-
kin-6 may provide a mitogenic stimulus resulting in
enhanced proliferation of HIV in patients co-infected
with both viruses, in addition to supporting the survival
of infected lymphocytes, thus predisposing them to
transforming events [21-25]. Our HIV-negative patient
had no evidence of infection by HHV-8.
It is unclear if PBL is associated with a relative state of
immunosuppression in HIV-negative patients. Although
our patient was HIV negative, it is possible the recurrent
problems with abscess formation and fistulas may have
led to a state of relative immunosuppression and devel-
opment of lymphoma, or the ongoing inflammation may
have promoted survival of lymphocytes which then
underwent further transforming events. Alternatively,
the recurrent abscesses may have been secondary to a
previously unrecognized state of relative immunosup-
pression, as indicated by the decrease in gamma globu-
lins demonstrated on serum protein electrophoresis. In
a case series reported by Teruya-Feldstein et al. [26],
two out of six cases of PBL in HIV-negative individuals
occurred in the setting of iatrogenic immunosuppres-
sion; one was a recipient of a renal allograft with locali-
zation of PBL to the skin of the leg [27] and the other a
patient with ulcerative colitis receiving azathioprine [28].
Both cases were EBV positive. It has been documented
that EBV-positive Hodgkin lymphoma may be associated
with Crohn’s disease [29,30], providing further sugges-
tion that immune dysregulation may play a role in the
development of PBL. While a minority of HIV-negative
patients have EBV-positive NHL, EBV positivity is more
frequently associated with immunosuppression-related
lymphoma, and the EBV positivity of the PBL in our
patient further supports that he may have had a state of
relative immunosuppression.
A  B 
C  D 
Figure 2 Immunohistochemical staining (a) CD45 (b) CD20 (c) CD138 (d) EBER.
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early stage include CHOP or similar chemotherapy regi-
mens, with or without involved field radiation therapy.
In the case studies of HIV-negative individuals with
PBL, all including our patient received CHOP. Future
therapies may take into account the infection of lym-
phoma cells with EBV and possibly HHV-8, and the
similarities of these cells to plasma cells, and may direct
therapy toward these specific features.
Conclusion
We report a case of a patient with PBL, an aggressive
NHL usually associated with significant and documented
immunosuppression, which can occur in immunocom-
petent individuals, most usually in the gastrointestinal
tract. Biopsy, with accurate pathological and immuno-
histological testing is essential for the correct diagnosis
and planning subsequent therapy.
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